Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Thiamine wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
7 of 12 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Dulaglutide and Thiamine have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.
any
Subcutaneous once-weekly pen (Trulicity)
50-100mg daily; 150-600mg benfotiamine for neuropathy
With food, Morning with other B vitamins
Benfotiamine (fat-soluble, higher bioavailability)
Weeks to months
Months to years
Months
Especially during initiation/escalation
2-4 weeks
4-8 weeks
4-12 weeks
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol (2019) · Meta analysis
Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome
Dietary supplements for dysmenorrhoea
The Cochrane database of systematic reviews (2016) · Meta analysis · n=3101
Supplements versus other supplementsThere was no evidence of a difference in effectiveness between ginger and zinc sulphate (MD 0.02 points, 95% CI -0.58 to 0.62; one RCT, 101 women).
Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients
Nutrients (2024) · Rct · n=122
Both groups showed pain improvement, but the VAS reduction (control: 24.58 vs. experimental: 31.35) was not statistically significant.
Efficacy of B-vitamins and vitamin D therapy in improving depressive and anxiety disorders: a systematic review of randomized controlled trials
Nutritional neuroscience (2023) · Systematic review · n=2256
Systematic review examining Thiamine efficacy
Based on limited RCT evidence showing VAS pain reduction with B-vitamin combinations. Effect magnitude conservative due to mixed statistical significance. Higher bioavailability forms like benfotiamine likely more effective than standard thiamine HCl.
AI-estimated from published studies. Interpret as directional guidance.
Thiamine has a higher evidence score (7.5/10 vs 7/10) and wins in 3 of 3 categories.
No known interactions between Dulaglutide and Thiamine have been documented in our database. However, always consult a healthcare provider before combining supplements.